Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scleroderma mystery: could a simple hormone be involved?

NCT ID NCT04746313

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether people with systemic sclerosis (scleroderma) have higher levels of the hormone prolactin in their blood. Researchers measured prolactin in 71 patients and compared them to healthy volunteers. The goal was to understand if prolactin plays a role in the disease, not to test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

71 people

The number who actually took part.

Started

Mar 2021

Finished

May 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Scleroderma patients are from scheduled hospitalization Department of Internal Medicine and Clinical Immunology, CHU Lille Healthy subjects are from the French Blood Establishment (EFS) and matched to scleroderma patients on age (+/- 5 years) and sex

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Scleroderma patients: * man or woman over 18 years old * with systemic sclerosis meeting ACR-EULAR 2013 criteria * having given his no opposition * being social insured Healthy subjects: * man or woman over 18 years old * donation of blood to the EFS * matched on age (+/- 5 years) and sex * having given his no opposition Exclusion Criteria: * Man or woman under 18 years old * Pregnant or breastfeeding women * Receiving medical treatment inducing dysfunction of the hypothalamic pituitary axis * Refusing or unable to give no objection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hyperprolactinemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse scleroderma hyperprolactinemia scleroderma systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hyperprolactinemia Scleroderma Sclerosis, systemic

Contacts and locations

Locations

  • Hop Claude Huriez Chu Lille

    Lille, 59037, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.